AMGN - AMGEN INC
303.01
-1.670 -0.551%
Share volume: 3,258,824
Last Updated: Fri 21 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.34%
PREVIOUS CLOSE
CHG
CHG%
$304.68
5.08
0.02%
Fundamental analysis
59%
Profitability
70%
Dept financing
26%
Liquidity
27%
Performance
63%
Performance
5 Days
3.49%
1 Month
10.81%
3 Months
2.88%
6 Months
-6.63%
1 Year
6.25%
2 Year
28.31%
Key data
Stock price
$303.01
DAY RANGE
$297.19 - $305.33
52 WEEK RANGE
$253.30 - $346.85
52 WEEK CHANGE
$5.81
DIVIDEND
$2.38
EX-DIVIDEND DATE
02/14/2025
NEXT EARNINGS DATE
N/A
Company detail
CEO: Robert A. Bradway
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Recent news